Vancomycin: A Literature Course on What the Studies Report

Vancomycin is one of the oldest antibiotics still in routine hospital use, and it is unusual among the compounds covered on PeptideU because it is a glycopeptide — a non-ribosomally assembled peptide scaffold decorated with sugars — rather than a signalling peptide. This course walks through six modules: what the compound is, how its mechanism is described, what outcomes individual studies reported, what the adverse-event literature documents, what is known about its pharmacokinetic monitoring, and how it is regulated. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medication. Nothing here is a protocol, and no module tells a reader what to do.

Module 1: What Vancomycin Is and How It Has Been Studied

Vancomycin is a tricyclic glycopeptide antibiotic originally isolated from a soil actinomycete. A historical review in Clinical Infectious Diseases traced the compound from its discovery in a soil sample through its rapid introduction in the 1950s, the impurity problems of early preparations, and its later return to prominence as methicillin-resistant staphylococci spread through hospitals (PMID 16323120). That review is a narrative history rather than an experiment, and the authors framed the drug's trajectory as one shaped by manufacturing chemistry and changing resistance patterns as much as by controlled trials.

Forms described in the literature

• Intravenous vancomycin — the systemic form discussed in the nephrotoxicity and monitoring literature, including a 2025 Australian Prescriber practice review on safe and effective use (PMID 40343139).
• Oral vancomycin — a gut-directed form examined in a 2025 Inflammatory Bowel Diseases paper on inflammatory pouch conditions associated with primary sclerosing cholangitis (PMID 40587335).
• Chemically modified analogues — laboratory derivatives such as the lipophilic-vancomycin-carbohydrate conjugates synthesised to act against vancomycin-resistant bacteria (PMID 25351946).
• Chemical-biology probes — diazirine photoprobes built on the vancomycin scaffold to identify vancomycin-binding proteins (PMID 38645928).

Limits of the evidence in Module 1

The historical account is a review and does not report primary outcome data. The verified papers in this course do not include a comprehensive efficacy trial programme, so the descriptions of forms above indicate what has been studied and published, not how any form performs relative to another.

Module 2: Mechanism as Described in the Literature

Vancomycin is described as acting outside the bacterial cell, binding the D-alanyl-D-alanine terminus of peptidoglycan precursors and blocking the cross-linking steps that build the cell wall. Because that target is a substrate rather than an enzyme, resistance arises when bacteria remodel the terminus itself. Work on vancomycin-resistant organisms was the explicit starting point for a 2015 synthetic chemistry study, in which researchers prepared lipophilic-vancomycin-carbohydrate conjugates and tested them against vancomycin-resistant bacteria to see whether added lipophilic and carbohydrate elements could restore activity (PMID 25351946).

Binding partners beyond the wall precursor

A 2024 chemical-biology study in ACS Bio & Med Chem Au approached mechanism from the opposite direction: rather than assuming a single target, the study used diazirine photoprobes derived from vancomycin to crosslink and identify proteins that bind the antibiotic (PMID 38645928). This kind of probe chemistry is a target-identification tool, and the authors reported it as a method for mapping vancomycin-binding proteins rather than as a clinical finding.

Resistance that is not always visible

Mechanism also interacts with diagnostics. A 2015 Journal of Clinical Microbiology report described vancomycin-variable enterococcal bacteremia, in which isolates carried vancomycin-resistance genetic elements while testing as susceptible by routine phenotypic methods (PMID 26424845). The relevance of that report is mechanistic as much as microbiological: the genotype and the laboratory phenotype did not agree.

Limits of the evidence in Module 2

The mechanistic papers here are laboratory and microbiology studies. Neither the conjugate chemistry (PMID 25351946) nor the photoprobe work (PMID 38645928) was a clinical trial, and neither established that any mechanistic observation translates into a patient-level outcome.

Module 3: Reported Outcomes by Study

The verified literature for this course spans clinical practice reviews, a gastroenterology therapeutic review, microbiological case material and preclinical chemistry. The table summarises what each examined and what was reported.

The oral, gut-directed line of work

The most recent therapeutic question in this set concerns oral vancomycin outside of its familiar infectious-disease indication. The 2025 Inflammatory Bowel Diseases paper positioned oral vancomycin as an emerging therapy for inflammatory pouch conditions occurring alongside primary sclerosing cholangitis (PMID 40587335). An "emerging therapy" framing in a review is a statement about where a literature currently sits, not a demonstration of benefit, and the paper does not convert into guidance for any individual.

Limits of the evidence in Module 3

None of the cited outcome papers is a large randomised controlled trial with hard endpoints. Reviews aggregate the judgement of their authors; microbiology reports describe small numbers of isolates or patients; preclinical chemistry reports activity in laboratory systems. Readers should treat every row of the table above as a description of what was published, not as evidence that a result would repeat in another population.

Module 4: Vancomycin Side Effects: What Studies Report

This is the largest and most consistent body of published material on vancomycin. The adverse events below are drawn only from the verified papers, and each is stated as the source reported it.

Kidney injury

A 2017 review in Clinical Pharmacology and Therapeutics was devoted entirely to the nephrotoxicity of vancomycin, examining how kidney injury associated with the drug has been defined, measured and attributed across the literature (PMID 28474732). Two further papers described a specific histological pattern: a 2017 JASN report characterised vancomycin-associated cast nephropathy (PMID 28082518), and a 2021 Kidney International Reports paper examined vancomycin-associated tubular casts in relation to vancomycin nephrotoxicity (PMID 34307986). Together these reports described an obstructive, cast-forming form of tubular injury rather than a purely functional change in laboratory values.

Infusion reactions

A dedicated reference chapter on vancomycin infusion reaction describes the flushing, rash and upper-body erythema historically labelled "red man syndrome", together with its recognition and management in clinical settings (PMID 29494112). The 2025 practice review also addressed administration-related safety as part of its discussion of safe and effective use (PMID 40343139).

Haematological effects

A 2024 report in Pharmacy described two cases of vancomycin-induced neutropenia, presenting them as recognised but uncommon drug-associated events (PMID 38392944). Case reports of this kind establish that an event has been observed and documented; they do not establish how often it occurs.

Cutaneous and vascular reactions

A 2018 case report in Journal of Investigative Medicine High Impact Case Reports described vancomycin-induced leukocytoclastic vasculitis, explicitly characterising it as a rare presentation (PMID 30622993).

Limits of the evidence in Module 4

Case reports and case series cannot generate incidence rates, and reviews of nephrotoxicity depend on how kidney injury was defined in the underlying studies (PMID 28474732). Hospitalised patients receiving vancomycin frequently receive other nephrotoxic agents and have competing illnesses, so attribution of any single event to the drug is inherently uncertain. The absence of an event from this list does not mean it has never been reported elsewhere; it means the verified papers assembled for this course did not document it.

Module 5: Pharmacokinetics Where Data Exist

Vancomycin is one of the few antibiotics for which routine therapeutic drug monitoring is standard practice, and the 2025 Australian Prescriber review on safe and effective use was written around exactly that issue, summarising monitoring and prescribing considerations for clinicians (PMID 40343139). The reason monitoring exists at all is the exposure–toxicity relationship discussed in the nephrotoxicity review, which examined how measures of vancomycin exposure have been related to kidney injury in the published literature (PMID 28474732).

Route matters for exposure. The systemic literature — nephrotoxicity, cast nephropathy, infusion reactions — concerns intravenous administration (PMID 28082518), while the gastrointestinal literature concerns an oral form used for its action within the gut, as described in the 2025 review of oral vancomycin in inflammatory pouch conditions (PMID 40587335).

Limits of the evidence in Module 5

This course deliberately states no numeric doses, target concentrations or infusion durations, because the verified papers listed here are not the appropriate source for reproducing such figures outside of clinical practice. Pharmacokinetic parameters vary with renal function, body size, critical illness and dialysis status, and no summary page can substitute for prescribing information or clinician judgement.

Module 6: Regulatory Status, Stated Factually

Vancomycin is not a research-use-only compound. Vancomycin hydrochloride is an approved prescription medicine in the United States, Australia and most other regulated markets, marketed in intravenous formulations and in oral formulations including capsules and, in some jurisdictions, an approved oral solution. Because it is a prescription antibiotic rather than an investigational peptide, it is dispensed through pharmacies on prescription and is not lawfully sold as a supplement or as a "research chemical".

Historically, oral liquid vancomycin was prepared by pharmacies from injectable product where no licensed oral liquid existed; compounding of that kind is governed in the United States by federal and state pharmacy law, including the framework for compounding pharmacies and outsourcing facilities. Chemically modified derivatives such as lipophilic-vancomycin-carbohydrate conjugates are laboratory constructs and are not approved medicines (PMID 25351946), as are vancomycin-based diazirine photoprobes used as research reagents (PMID 38645928). National prescribing guidance, such as the 2025 Australian review, exists precisely because approved use is accompanied by formal monitoring expectations (PMID 40343139).

This regulatory summary is general information and is not legal advice; rules differ by country and by state and change over time.

Limits of the evidence in Module 6

Regulatory status is jurisdictional and time-sensitive. Approval in one country does not imply approval in another, and approval for one indication does not imply approval for the gastrointestinal uses discussed in the emerging-therapy literature (PMID 40587335).

What the Studies Did Not Test

• Use outside medical supervision. No cited paper examined vancomycin use without prescribing, laboratory monitoring or clinical oversight, and the monitoring literature exists because exposure is tracked in care settings (PMID 40343139).
• Healthy-volunteer or wellness contexts. The nephrotoxicity and cast nephropathy literature was generated in patients treated for infection, not in healthy individuals (PMID 34307986).
• Incidence of rare reactions. Case reports of neutropenia and leukocytoclastic vasculitis documented occurrence, not frequency (PMID 38392944, PMID 30622993).
• Long-term outcomes of oral, gut-directed use. The 2025 review described an emerging therapy rather than long-term controlled outcome data (PMID 40587335).
• Clinical performance of analogues. Conjugate chemistry was reported in laboratory systems against resistant bacteria, with no human data in that report (PMID 25351946).
• Diagnostic certainty. The vancomycin-variable enterococcus report showed that standard susceptibility testing did not always capture resistance genetics (PMID 26424845).

Read together, the literature summarised here describes an old antibiotic with a well-characterised target, a persistent resistance problem, a monitored exposure profile and a documented set of adverse events — and a set of open questions that the published work has not yet answered.

References

• Vancomycin: a history (Clinical Infectious Diseases, 2006)
• Vancomycin-Variable Enterococcal Bacteremia (Journal of Clinical Microbiology, 2015)
• Tackling vancomycin-resistant bacteria with 'lipophilic-vancomycin-carbohydrate conjugates' (The Journal of Antibiotics, 2015)
• Vancomycin-Associated Cast Nephropathy (JASN, 2017)
• The Nephrotoxicity of Vancomycin (Clinical Pharmacology and Therapeutics, 2017)
• Vancomycin-Induced Leukocytoclastic Vasculitis: A Rare Case Report (Journal of Investigative Medicine High Impact Case Reports, 2018)
• Vancomycin Infusion Reaction (StatPearls)
• Vancomycin-Associated Tubular Casts and Vancomycin Nephrotoxicity (Kidney International Reports, 2021)
• Two Cases of Vancomycin-Induced Neutropenia (Pharmacy, 2024)
• Diazirine Photoprobes for the Identification of Vancomycin-Binding Proteins (ACS Bio & Med Chem Au, 2024)
• Safe and effective use of vancomycin (Australian Prescriber, 2025)
• Oral Vancomycin as an Emerging Therapy for Inflammatory Pouch Conditions Associated With Primary Sclerosing Cholangitis (Inflammatory Bowel Diseases, 2025)